Aging and liver disease

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 184-191

  Kim, In Hee ^a   Kisseleva, Tatiana ^b   Brenner, David A ^b  

^a Chonbuk National University Medical School   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aging; liver; nonalcoholic steatohepatitis; senescence; transplantation

Indexed keywords

AGING; ALCOHOL LIVER DISEASE; CELLS; CHRONIC HEPATITIS C; HUMAN; LIVER BLOOD FLOW; LIVER DISEASE; LIVER FIBROSIS; LIVER FUNCTION; LIVER INJURY; LIVER REGENERATION; LIVER TRANSPLANTATION; LIVER WEIGHT; NONALCOHOLIC FATTY LIVER; REVIEW; VIRUS HEPATITIS; AGED; CHRONIC DISEASE; COMORBIDITY; COMPLICATION; DISEASE COURSE; HOMEOSTASIS; MIDDLE AGED; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; CHRONIC DISEASE; COMORBIDITY; DISEASE PROGRESSION; HOMEOSTASIS; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MIDDLE AGED; OBESITY;

EID: 84928537303     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000176     Document Type: Review

References (84)

1. López-Otń C, Blasco MA, Partridge L, et al. The hallmarks of aging. Cell 2013; 153:1194-1217.
2. WHO. Global health and aging. Geneva: World Health Organization; 2011.
3. Prevention CfDCa. The state of aging and health in America 2013. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
4. Schmucker DL. Age-related changes in liver structure and function: implications for disease? Exp Gerontol 2005; 40:650-659.
5. Le Couteur DG, Warren A, Cogger VC, et al. Old age and the hepatic sinusoid. Anat Rec (Hoboken) 2008; 291:672-683.
6. Floreani A. Liver diseases in the elderly: An update. Dig Dis 2007; 25:138-143.
7. Amarapurkar D, Kamani P, Patel N, et al. Prevalence of nonalcoholic fatty liver disease: population based study. Ann Hepatol 2007; 6:161-163.
8. Sheedfar F, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? Aging Cell 2013; 12:950-954.
9. Wynne HA, Cope LH, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9:297-301.
10. Le Couteur DG, McLean AJ. The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34:359-373.
11. Iber FL, Murphy PA, Connor ES. Age-related changes in the gastrointestinal system. Effects on drug therapy. Drugs Aging 1994; 5:34-48.
12. Zoli M, Magalotti D, Bianchi G, et al. Total and functional hepatic blood flow decrease in parallel with ageing. Age Ageing 1999; 28:29-33.
13. Wakabayashi H, Nishiyama Y, Ushiyama T, et al. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. J Surg Res 2002; 106:246-253.
14. Tietz NW, Shuey DF, Wekstein DR. Laboratory values in fit aging individuals: sexagenarians through centenarians. Clin Chem 1992; 38:1167-1185.
15. Hohn A, Grune T. Lipofuscin: formation, effects and role of macroautophagy. Redox Biol 2013; 1:140-144.
16. Le Couteur DG, Cogger VC, Markus AM, et al. Pseudocapillarization and associated energy limitation in the aged rat liver. Hepatology 2001; 33:537-543.
17. Sastre J, Pallardo FV, Pla R, et al. Aging of the liver: Age-associated mitochondrial damage in intact hepatocytes. Hepatology 1996; 24:1199-1205.
18. Toomajian C, Ajioka RS, Jorde LB, et al. A method for detecting recent selection in the human genome from allele age estimates. Genetics 2003; 165:287-297.
19. McLean AJ, Cogger VC, Chong GC, et al. Age-related pseudocapillarization of the human liver. J Pathol 2003; 200:112-117.
20. Ito Y, Sorensen KK, Bethea NW, et al. Age-related changes in the hepatic microcirculation in mice. Exp Gerontol 2007; 42:789-797.
21. Warren A, Le Couteur DG, Fraser R, et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 2006; 44:1182-1190.
22. Baynes JW. The role of AGEs in aging: causation or correlation. Exp Gerontol 2001; 36:1527-1537.
23. Hilmer SN, Cogger VC, Le Couteur DG. Basal activity of Kupffer cells increases with old age. J Gerontol A Biol Sci Med Sci 2007; 62:973-978.
24. Warren A, Cogger VC, Fraser R, et al. The effects of old age on hepatic stellate cells. Curr Gerontol Geriatr Res 2011; 2011:439835.
25. Verma S, Tachtatzis P, Penrhyn-Lowe S, et al. Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver. Hepatology 2012; 56:1510-1520.
26. Poulose N, Raju R. Aging and injury: Alterations in cellular energetics and organ function. Aging Dis 2014; 5:101-108.
27. Giavarotti L, D'Almeida V, Giavarotti KA, et al. Liver necrosis induced by acute intraperitoneal ethanol administration in aged rats. Free Radic Res 2002; 36:269-275.
28. Sanz N, Diez-Fernandez C, Andres D, Cascales M. Hepatotoxicity and aging: endogenous antioxidant systems in hepatocytes from 2-, 6-, 12-, 18-and 30-month-old rats following a necrogenic dose of thioacetamide. Biochim Biophys Acta 2002; 1587:12-20.
29. Bloomer SA, Zhang HJ, Brown KE, Kregel KC. Differential regulation of hepatic heme oxygenase-1 protein with aging and heat stress. J Gerontol A Biol Sci Med Sci 2009; 64:419-425.
30. Lopez-Diazguerrero NE, Luna-Lopez A, Gutierrez-Ruiz MC, et al. Susceptibility of DNA to oxidative stressors in young and aging mice. Life Sci 2005; 77:2840-2854.
31. Hong IH, Lewis K, Iakova P, et al. Age-associated change of C/EBP family proteins causes severe liver injury and acceleration of liver proliferation after CCl4 treatments. J Biol Chem 2014; 289:1106-1118.
32. Sanz N, Diez-Fernandez C, Alvarez AM, et al. Age-related changes on parameters of experimentally-induced liver injury and regeneration. Toxicol Appl Pharmacol 1999; 154:40-49.
33. Timchenko NA. Aging and liver regeneration. Trends Endocrinol Metab 2009; 20:171-176.
34. Iakova P, Awad SS, Timchenko NA. Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 2003; 113:495-506.
35. Wang GL, Salisbury E, Shi X, et al. HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta. J Biol Chem 2008; 283:26179-26187.
36. Iwaisako K, Brenner DA, Kisseleva T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol 2012; 27 (Suppl 2): 65-68.
37. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34:730-739.
38. Forrest EH, Evans CD, Stewart S, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54:1174-1179.
39. Mahrouf-Yorgov M, de L'hortet AC, Cosson C, et al. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. Rejuvenation Res 2011; 14:353-363.
40. Collins BH, Holzknecht ZE, Lynn KA, et al. Association of age-dependent liver injury and fibrosis with immune cell populations. Liver Int 2013; 33:1175-1186.
41. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142:1592-1609.
42. Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of nonalcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006; 21:138-143.
43. Koehler EM, Schouten JN, Hansen BE, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 2012; 57:1305-1311.
44. Frith J, Day CP, Henderson E, et al. Nonalcoholic fatty liver disease in older people. Gerontology 2009; 55:607-613.
45. Noureddin M, Yates KP, Vaughn IA, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology 2013; 58:1644-1654.
46. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes 2012; 61:1315-1322.
47. Aravinthan A, Scarpini C, Tachtatzis P, et al. Hepatocyte senescence predicts progression in nonalcohol-related fatty liver disease. J Hepatol 2013; 58:549-556.
48. Jin J, Iakova P, Breaux M, et al. Increased expression of enzymes of triglyceride synthesis is essential for the development of hepatic steatosis. Cell Rep 2013; 3:831-843.
49. Amir M, Czaja MJ. Autophagy in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011; 5:159-166.
50. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging: An evolutionary perspective on immunosenescence. Ann NY Acad Sci 2000; 908:244-254.
51. Shah K, Stufflebam A, Hilton TN, et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009; 17:2162-2168.
52. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364:1218-1229.
53. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med 2007; 356:2176-2183.
54. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004; 39:1647-1654.
55. Varela JE, Wilson SE, Nguyen NT. Outcomes of bariatric surgery in the elderly. Am Surg 2006; 72:865-869.
56. Blazer DG, Wu LT. The epidemiology of at-risk and binge drinking among middle-aged and elderly community adults: National Survey on Drug Use and Health. Am J Psychiatry 2009; 166:1162-1169.
57. Meier P, Seitz HK. Age, alcohol metabolism and liver disease. Curr Opin Clin Nutr Metab Care 2008; 11:21-26.
58. Seitz HK, Stickel F. Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress. Biol Chem 2006; 387:349-360.
59. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
60. Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805-809.
61. Westin J, Nordlinder H, Lagging M, et al. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37:837-842.
62. McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14:381-396.
63. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007; 106:148-155.
64. Cozzolongo R, Osella AR, Elba S, et al. Epidemiology of HCV infection in the general population: A survey in a southern Italian town. Am J Gastroenterol 2009; 104:2740-2746.
65. Tanaka J, Kumagai J, Katayama K, et al. Sex-and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 2004; 47:32-40.
66. Dominguez A, Bruguera M, Vidal J, et al. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001; 65:688-693.
67. Gramenzi A, Conti F, Camma C, et al. Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver. Dig Liver Dis 2012; 44:674-680.
68. Thabut D, Le Calvez S, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: A severe and neglected curable disease? Am J Gastroenterol 2006; 101:1260-1267.
69. Ryder SD, Irving WL, Jones DA, et al., Trent Hepatitis CSG. Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004; 53:451-455.
70. Malnick S, Maor Y, Melzer E, Tal S. Chronic hepatitis C in the aged: much ado about nothing or nothing to do? Drugs Aging 2014; 31:339-347.
71. Huang CF, Chuang WL, Yu ML. Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci 2011; 27:533-537.
72. Kainuma M, Furusyo N, Kajiwara E, et al. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16:4400-4409.
73. Abu-Mouch S, Fireman Z, Jarchovsky J, et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naive patients. World J Gastroenterol 2011; 17:5184-5190.
74. Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut 2013; 62:766-773.
75. Furusyo N, Ogawa E, Nakamuta M, et al. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol 2013; 59:205-212.
76. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211-221.
77. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
78. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146:1176-1192.
79. Aberg F, Isoniemi H, Hockerstedt K. Long-term results of liver transplantation. Scand J Surg 2011; 100:14-21.
80. Randall HB, Cao S, deVera ME. Transplantation in elderly patients. Arch Surg 2003; 138:1089-1092.
81. Zetterman RK, Belle SH, Hoofnagle JH, et al. Age and liver transplantation: A report of the Liver Transplantation Database. Transplantation 1998; 66:500-506.
82. Adani GL, Baccarani U, Lorenzin D, et al. Elderly versus young liver transplant recipients: patient and graft survival. Transplant Proc 2009; 41:1293-1294.
83. Shankar N, AlBasheer M, Marotta P, et al. Do older patients utilize excess healthcare resources after liver transplantation? Ann Hepatol 2011; 10:477-481.
84. Aloia TA, Knight R, Gaber AO, et al. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors. Liver Transpl 2010; 16:950-959.